Eumovate

Eumovate contains clobetasone butyrate, a moderately potent topical corticosteroid used for the treatment of mild to moderate inflammatory skin conditions such as eczema, dermatitis, and insect bite reactions.

It is available without prescription for short-term use.

Clobetasone butyrate suppresses the inflammatory and immune responses in the skin by inhibiting the release of pro-inflammatory mediators, reducing capillary permeability, and limiting the migration of inflammatory cells into the affected area.

This results in decreased redness, swelling, itching, and discomfort.

Eumovate occupies a middle position in the corticosteroid potency ladder, sitting between mild preparations such as hydrocortisone 1% and potent preparations such as betamethasone valerate.

This makes it a useful step-up option when hydrocortisone alone is insufficient, while carrying a lower risk of side effects than potent corticosteroids.

It is available as a cream and an ointment. The cream is suitable for most skin conditions, while the ointment is preferred for dry or thickened skin.

Eumovate can be purchased over the counter for the treatment of eczema and dermatitis in adults, but prescription supervision is recommended for prolonged or widespread use.

Apply a thin layer of Eumovate to the affected area once or twice daily. Gently massage the preparation into the skin until absorbed.

Wash your hands after application unless you are treating the hands.

Use the smallest effective amount for the shortest time necessary. When the condition improves, reduce the frequency of application or switch to an emollient alone.

Do not apply to the face for more than five days unless specifically directed by your doctor.

If there is no improvement after seven days of over-the-counter use, consult a pharmacist or doctor for further assessment.

Apply thinly to the affected area once or twice daily. For over-the-counter use, treatment should not exceed seven days without medical advice.

Under prescription supervision, longer courses may be appropriate but should be reviewed regularly.

Eumovate is suitable for adults and children over 12 years for over-the-counter use. In younger children, it should be used under medical supervision.

The fingertip unit method helps to gauge the correct amount.

Side effects from short-term, localised use are uncommon.

Prolonged or extensive application may cause skin thinning, striae (stretch marks), and telangiectasia (visible small blood vessels), particularly on the face, flexures, and skin folds.

Contact dermatitis (allergic reaction to the cream or an excipient) may develop. A mild burning or stinging sensation upon application is occasionally reported.

On the face, prolonged use may trigger perioral dermatitis or acneiform eruptions. Depigmentation at the application site has been noted rarely.

Systemic absorption is generally negligible at recommended doses, but extensive use over large areas could theoretically lead to adrenal suppression, particularly in children.

Do not use Eumovate on infected skin unless an antimicrobial agent is being used concurrently. Topical corticosteroids can mask the signs of infection and allow it to worsen.

If infection develops during treatment, stop the corticosteroid and seek medical advice.

Avoid applying Eumovate to the face, groin, or axillae for extended periods. These areas have thinner skin and are more susceptible to corticosteroid-induced side effects.

Keep the preparation away from the eyes.

Inform your pharmacist or doctor if you are pregnant, breastfeeding, or using other topical treatments on the same area.

Eumovate must not be applied to untreated bacterial, viral, or fungal skin infections, including cold sores, chickenpox, and ringworm.

It is contraindicated in acne vulgaris, rosacea, perioral dermatitis, and nappy rash.

Do not use if you have a known allergy to clobetasone butyrate or any ingredient in the formulation.